Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform.

969 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Nanoparticles offer the possibility to encapsulate poorly soluble drugs [8, 9], protect therapeutic molecules [10], and modify their blood circulation and tissue distribution profiles [11, 12].”
Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine (2019, methodology): “In MSNs/lipid bilayer hybrid nanocarriers, lipid bilayers are used to cap the MSN channels to prevent premature release of loaded drug, circumvent multidrug resistance, prolong retention of hydrophilic drug cargo, and achieve stimulus-responsive drug release [154, 155].”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, methodology): “Consequently, the oil phase is evaporated from the w/o/w emulsion forming LPNs (Cheow and Hadinoto, 2011).”
Single-step assembly of DOX/ICG loaded lipid--polymer nanoparticles for highly effective chemo-photothermal combination therapy. (2013, positive): “The lipid-polymer hybrid NPs can take the unique advantages of polymeric NPs and liposomes and become a robust drug delivery platform with high drug encapsulating, tunable, and sustained drug release, excellent serum stability, and potential for differential targeting of cells or tissues.(15) 18 Doc”